Management and outcome of metastatic pheochromocytomas/paragangliomas: an overview

@article{Filpo2020ManagementAO,
  title={Management and outcome of metastatic pheochromocytomas/paragangliomas: an overview},
  author={G. De Filpo and M. Maggi and M. Mannelli and L. Canu},
  journal={Journal of Endocrinological Investigation},
  year={2020},
  volume={44},
  pages={15-25}
}
  • G. De Filpo, M. Maggi, +1 author L. Canu
  • Published 2020
  • Medicine
  • Journal of Endocrinological Investigation
  • Background Metastatic pheochromocytomas and paragangliomas (PPGLs) occur in about 5–26% of cases and are characterized by a heterogeneous prognosis. Metastases can be synchronous at the initial diagnosis, but they can occur also many years after surgery for the primary tumor. To date, the treatment of patients affected by metastatic PPGLs represents a clinical challenge because of the lack of guidelines. Aim The aim of this article is to review the available management options and their impact… CONTINUE READING

    References

    SHOWING 1-10 OF 71 REFERENCES
    Metastatic pheochromocytoma and paraganglioma: recent advances in prognosis and management
    • Oksana Hamidi
    • Medicine
    • Current opinion in endocrinology, diabetes, and obesity
    • 2019
    • 7
    Treatment for Malignant Pheochromocytomas and Paragangliomas: 5 Years of Progress
    • 29
    • Highly Influential
    Antiangiogenic therapies for pheochromocytoma and paraganglioma.
    • 3
    • Highly Influential
    • PDF
    Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years
    • 86
    • PDF
    Clinical review: Current treatment of malignant pheochromocytoma.
    • 162
    • PDF
    Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma.
    • 80
    • PDF
    Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer
    • 23
    • PDF